Nefroblastomani davolash natijalari: Milliy bolalar tibbiyot markazining tajribasi va personalizatsiyalangan terapiya kelajagi
Referat
Ma'qsad: Bolalardagi nefroblastomani davolashda kombinatsiyalangan terapiyaning samaradorligini baholash, jumladan, ximioterapiya, jarrohlik aralashuvi va radioterapiya, shuningdek, bemorlarning omon qolishiga ta'sir etuvchi prognoz omillarini o'rganish.
Materiallar va usullar: Tadqiqot 2021 yil yanvaridan 2025 yil martigacha Milliy bolalar tibbiyot markazida davolangan morfologik jihatdan tasdiqlangan nefroblastomali 45 nafar pediatrik bemor bilan retrospektiv kohort analiz sifatida o'tkazildi. Barcha bemorlar ultratovush, multisprialli KT, PET/KT va MRT orqali diagnostika qilingan. Davolashga radikal nefrektomiya va limfodiseksiyani o'z ichiga olgan jarrohlik aralashuvi, shuningdek, xalqaro protokollar bo'yicha adyuvant ximioterapiya kirgan.
Natijalar: Umumiy 3 va 5 yillik omon qolish darajasi 85.6% ni tashkil etdi. Kasallikning qaytalanishi 2.2% bemorlarda qayd etilgan. Metastazlar 15.5% holatlarda kuzatilgan, shu jumladan, faqat o'pka (6.6%) va retroperitoneal limfa tugunlari (4.4%) zararlanishi. O'lim darajasi 15.5% ni tashkil etdi, va o'lim holatlarining 71.4% past differensatsiyalangan o'smalarga (G3) ega edi. Past differensatsiyalangan o'smalar (G3) metastazlarning oshgan xavfi bilan bog'liq edi (OR=3.8, p=0.021). Kasallikning erta bosqichi yaxshi prognoz bilan bog'liq edi.
Xulosa: Nefroblastomani davolashda jarrohlik aralashuvi, ximioterapiya va selektiv radioterapiya qo'llash orqali yuqori omon qolish (85.6%) ta'minlandi. Biroq, past differensatsiyalangan o'smalar yomon prognoz va yuqori metastaz xavfi bilan bog'liq. Kasallikni erta aniqlash, shuningdek, molekulyar-genetik profilga asoslangan personalizatsiyalangan yondashuv davolash natijalarini yaxshilashi mumkin.
Mualliflar haqida
Adabiyotlar ro'yxati
Spreafico F, Fernandez C V., Brok J, et al. Wilms tumour. Nat Rev Dis Primers; 7. Epub ahead of print 1 December 2021. DOI: 10.1038/s41572-021-00308-8.
Mahamdallie S, Yost S, Poyastro-Pearson E, et al. Identification of new Wilms tumour predisposition genes: an exome sequencing study. Lancet Child Adolesc Health 2019; 3: 322–331.
Dome JS, Perlman EJ, Graf N. Risk stratification for wilms tumor: current approach and future directions. Am Soc Clin Oncol Educ Book 2014; 215–223.
Elgenidy A, Afifi AM, Gad EF, et al. Survival characteristics of Wilms Tumor, a reference developed from a longitudinal cohort study. Ital J Pediatr; 50. Epub ahead of print 1 December 2024. DOI: 10.1186/S13052-024-01698-7.
Van Den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol 2017; 14: 743–752.
Jackson TJ, Brisse HJ, Pritchard-Jones K, et al. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group. Pediatr Blood Cancer; 69. Epub ahead of print 1 September 2022. DOI: 10.1002/PBC.29702.
Graf N, Tournade MF, De Kraker J. The role of preoperative chemotherapy in the management of Wilms’ tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am 2000; 27: 443–454.
Israels T, Molyneux EM. Lessons learned from a multicentre clinical trial in Africa. Nat Rev Clin Oncol 2019; 16: 211–212.
Pasqualini C, Furtwa¨ngler R, van Tinteren H, et al. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. Eur J Cancer 2020; 128: 38–46.
John R, Kurian JJ, Sen S, et al. Clinical outcomes of children with Wilms tumor treated on a SIOP WT 2001 protocol in a tertiary care hospital in south India. J Pediatr Urol 2018; 14: 547.e1-547.e7.
Weirich A, Ludwig R, Graf N, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 2004; 15: 808–820.
Sarin YK, Bhatnagar SN. Wilms’ tumor- roadmaps of management. Indian J Pediatr 2012; 79: 776–786.
Qi XW, Zhang F, Wu H, et al. Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep; 5. Epub ahead of print 9 March 2015. DOI: 10.1038/SREP08924.
Coppes MJ, De Kraker J, Van Dijken PJ, et al. Bilateral Wilms’ tumor: long-term survival and some epidemiological features. J Clin Oncol 1989; 7: 310–315.
Qanday qilib iqtibos keltirish mumkin
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.